GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Notes Receivable

BCAX (Bicara Therapeutics) Notes Receivable : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Notes Receivable?

Bicara Therapeutics's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.


Bicara Therapeutics Notes Receivable Historical Data

The historical data trend for Bicara Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Notes Receivable Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Notes Receivable
- - -

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial - - - - -

Bicara Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Bicara Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Bicara Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.